Table 1 Baseline characteristics and measurements of the total group, stratified by randomisation group
|  | Paracetamol-placebo, N = 47 | Placebo-paracetamol, N = 48 |
|---|---|---|
Mean age (SD) in years | 83.9 (7.5) | 83.9 (7.7) |
Female (%) | 27 (57.4) | 28 (58.3) |
GDS score 7 (%) | 10 (21.3) | 10 (20.8) |
FCI, 0–18 (SD) | 2.9 (1.9) | 2.5 (2.1) |
QUALIDEM-6D | ||
 Total score 0–100 (SD) | 58.1 (13.1) | 57.0 (13.8) |
 A—Care relationship 0–100 (SD) | 58.0 (22.3) | 56.9 (23.0) |
 B—Positive affect 0–100 (SD) | 69.6 (18.6) | 68.4 (19.7) |
 C—Negative affect 0–100 (SD) | 63.8 (28.0) | 64.2 (25.0) |
 D—Restless tense behaviour 0–100 (SD) | 37.9 (25.5) | 39.8 (28.6) |
 F—Social relationships 0–100 (SD) | 64.0 (21.2) | 58.8 (20.9) |
 G—Social isolation 0–100 (SD) | 55.1 (20.8) | 53.7 (23.7) |
DS-DAT, 0–27 (SD) | 8.4 (4.9) | 8.3 (6.0) |
Pain (MOBID-2 ≥ 3) (%) | 15 (33.3)* | 15 (31.3) |
MOBID-2 overall pain intensity, 0–10 (SD) | 2.0 (2.4) | 2.3 (3.0) |
NPI-NH | ||
 Total score, 0–144 (SD) | 32.6 (21.0) | 33.5 (18.9) |
 Psychosis 0–24 (SD) | 3.7 (5.8) | 3.7 (4.6) |
 Agitation 0–48 (SD) | 10.7 (8.6) | 11.9 (9.7) |
 Affective symptoms 0–24 (SD) | 5.9 (6.2) | 4.8 (5.7) |
No psychotropic use†(%) | 29 (61.7)** | 19 (39.6)** |